Hematopoiesis and Cancer
The research unit's objective in research on hematopoiesis and cancer is to advance our understanding of the molecular basis of physiology, ontogenesis, and the differentiation of blood cells, and to reveal the mechanisms leading to cancer in the hematopoietic system, i.e. leukemia and lymphoma. The research program focuses on the role transcription factors and chromatin regulators play, such as the zinc-finger proteins Gfi1 and Gfi1b and transcription factor POZ/BTB Miz-1.
The general approach used to understand the way they function is to generate mutant alleles by targeting genes in the mouse. This extremely powerful technique has given the team deeper insight into critical steps in hematopoietic differentiation, specifically stem cell self-renewal.
- Director, Hematopoiesis and Cancer research unit
- Full IRCM Research Professor
- Full Research Professor, Department of Microbiology, Infectiology and Immunology (accreditation in biochemistry and molecular medicine), Université de
- Adjunct professor, Department of Medicine (Division of Experimental Medicine), McGill University
- Tier 1 Canada Research Chairholder in Hematopoiesis and Immune Cell Differentiation
Boards of Directors
- Canadian Society for Molecular Biosciences (since 2015)
- Research Canada (since 2016)
Awards and honours
- Fellow of the Canadian Academy of Health Sciences (2018)
- Nomination as “Honory Guest Professor for outstanding achievements in immunology” at Beijing Ditan Hospital, Capital Medical University, Beijing, China (2015)
- Recognition award, Leukemia & Lymphoma Society of Canada (2014)
- “Community Shift” fellow, Ivey School of Business, UWO, London, Ontario (2013)
- Researcher of the month (January 2011), Canadians for Health Research
Degrees and experience
- M.Sc. in biochemistry, University of Tübingen, Germany
- PhD in biochemistry, Ludwig Maximilians University, Munich, Germany
- Postdoctoral fellowship, Columbia University, New York
- Habilitation thesis for research supervision, University of Marburg, Germany
- President and Scientific Director, IRCM (2006-2019)
Marneth AE, Botezatu L, Hönes JM, Israël JCL, Schütte J, Vassen L, Lams RF, Bergevoet SM, Groothuis L, Mandoli A, Martens JHA, Huls G, Jansen JH, Dührsen U, Berg T, Möröy T, Wichmann C, Lo MC, Zhang DE, van der Reijden BA, Khandanpour C, GFI1 is required for RUNX1/ETO positive acute myeloid leukemia. - Haematologica 2018 Sep
Hansen M, Varga E, Wüst T, Brouwer N, Beauchemin H, Mellink C, van der Kevie-Kersemaekers AM, Möröy T, van der Reijden B, von Lindern M, van den Akker E, Generation and characterization of human iPSC line MML-6838-Cl2 from mobilized peripheral blood derived megakaryoblasts. - Stem Cell Research 2017 Jan
Botezatu L, Michel LC, Helness A, Vadnais C, Makishima H, Hönes JM, Robert F, Vassen L, Thivakaran A, Al-Matary Y, Lams RF, Schütte J, Giebel B, Görgens A, Heuser M, Medyouf H, Maciejewski J, Dührsen U, Möröy T, Khandanpour C, Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. - Experimental Hematology 2016 Aug
Botezatu L, Michel LC, Makishima H, Schroeder T, Germing U, Haas R, van der Reijden B, Marneth AE, Bergevoet SM, Jansen JH, Przychodzen B, Wlodarski M, Niemeyer C, Platzbecker U, Ehninger G, Unnikrishnan A, Beck D, Pimanda J, Hellström-Lindberg E, Malcovati L, Boultwood J, Pellagatti A, Papaemmanuil E, Le Coutre P, Kaeda J, Opalka B, Möröy T, Dührsen U, Maciejewski J, Khandanpour C, GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome. - Experimental Hematology 2016 Jul
Hönes JM, Botezatu L, Helness A, Vadnais C, Vassen L, Robert F, Hergenhan SM, Thivakaran A, Schütte J, Al-Matary YS, Lams RF, Fraszscak J, Makishima H, Radivoyevitch T, Przychodzen B, da Conceição Castro SV, Görgens A, Giebel B, Klein-Hitpass L, Lennartz K, Heuser M, Thiede C, Ehninger G, Dührsen U, Maciejewski JP, Möröy T, Khandanpour C, GFI1 as a novel prognostic and therapeutic factor for AML/MDS. - Leukemia 2016 Jun
Spectator – IRCM researchers demonstrated that a protein called AXL influences the occurrence of metastasis in breast cancer patients.
ICI Première (Samedis du monde) – An IRCM discovery should allow patients with certain forms of blood cancer, leukemias and lymphomas to benefit from more effective treatments.
La Presse – Chemotherapy cannot always stop cancer. IRCM researchers just discovered one of the keys to this resistance.
Support biomedical research
Montreal Clinical Research Institute (IRCM)
110, des Pins Avenue West
Montréal, Québec H2W 1R7